ブリンゾラミド追加投与による眼圧への短期効果

Short-term hypotensive effect of additional brinzolamide in glaucoma treatment

　点眼薬で治療中の緑内障85例142眼に1％ブリンゾラミドを1日2回追加点眼し，3か月間の効果と副作用を検索した。緑内障の病型は，原発開放隅角緑内障75眼，正常眼圧緑内障48眼，その他19眼である。追加点眼前では，1剤投与が32眼，2剤以上が110眼であった。平均眼圧は，追加投与前17.4±3.1mmHg，投与開始1か月後15.0±2.9mmHg，2か月後14.9±2.9mmHg，3か月後14.9±2.9mmHgで，いずれも投与前よりも有意に低下した（p＜0.0001）。原発開放隅角緑内障，正常眼圧緑内障，追加点眼開始前に1剤および2剤以上の症例のすべてで，投与開始から1，2，3か月後の眼圧は投与前よりも有意に低下した（p＜0.0001）。霧視や異物感などの副作用が8例（9％）に生じた。ブリンゾラミドの追加点眼は安全であり，緑内障の病型あるいはそれまでの緑内障点眼薬の薬剤数にかかわらずいっそうの眼圧下降効果があると結論される。

　We evaluated the hypotensive effect of brinzolamide in 142 eyes of 85glaucoma patients as added to prior topical medications. The series comprised primary open-angle glaucoma 75 eyes,normal-tension glaucoma 48 eyes,and other glaucoma entities 19 eyes. Before start of brinzolamide,32 eyes and been receiving one medication and 110 eyes had been receiving two or more medications. The baseline intraocular pressure（IOP）averaged 17.4±3.1mmHg in the whole series. After start of 1％brinzolamide twice daily,the IOP averaged 15.0±2.9mmHg one month later,14.9±2.9mmHg 2months later,and 14.9±2.9mmHg 3months later. Each value was significantly lower than the baseline IOP（p＜0.0001）. During the 3-month treatment,the IOP decreased significantly than the baseline value in primary open-angle glaucoma,normal-tension glaucoma,and other glaucoma entities（p＜0.0001）. Minor adverse effect developed in 8 eyes（9％）. It is concluded that additional brinzolamide is safe and effective for various types of glaucoma.